Randomized trial comparing liposomal daunorubicin with idarubicin as induction for pediatric acute myeloid leukemia: results from Study AML-BFM 2004.

No abstract is available for this paper.

• Publication year

  2013

• Venue

  Blood

• Publication date

  2013-07-04

• Fields of study

  Medicine

• Identifiers
  DOI 10.1182/blood-2013-02-484097PMID 23704089
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Improved outcome in pediatric relapsed acute myeloid leukemia: results of a randomized trial on liposomal daunorubicin by the International BFM Study Group.

  2013cited by this paper
• The role of matched sibling donor allogeneic stem cell transplantation in pediatric high-risk acute myeloid leukemia: results from the AML-BFM 98 study

  2012cited by this paper
• Second induction with high-dose cytarabine and mitoxantrone: different impact on pediatric AML patients with t(8;21) and with inv(16).

  2011cited by this paper
• Response-guided induction therapy in pediatric acute myeloid leukemia with excellent remission rate.

  2011cited by this paper
• Results of a randomized trial in children with Acute Myeloid Leukaemia: Medical Research Council AML12 trial

  2011cited by this paper
• Anthracycline-Associated Cardiotoxicity in Survivors of Childhood Cancer

  2011cited by this paper
• CNS irradiation in pediatric acute myleoid leukemia: Equal results by 12 or 18 Gy in studies AML‐BFM98 and 2004

  2011cited by this paper
• Prognostic impact of specific chromosomal aberrations in a large group of pediatric patients with acute myeloid leukemia treated uniformly according to trial AML-BFM 98.

  2010cited by this paper
• Minimal residual disease-directed therapy for childhood acute myeloid leukaemia: results of the AML02 multicentre trial.

  2010cited by this paper
• Different anthracycline derivates for reducing cardiotoxicity in cancer patients.

  2010cited by this paper
• Cardiotoxicity after childhood cancer: beginning with the end in mind.

  2010cited by this paper
• Anthracycline dose intensification in acute myeloid leukemia.

  2009cited by this paper
• High-dose daunorubicin in older patients with acute myeloid leukemia.

  2009cited by this paper
• Risk-stratified therapy and the intensive use of cytarabine improves the outcome in childhood acute myeloid leukemia: the AML99 trial from the Japanese Childhood AML Cooperative Study Group.

  2009cited by this paper
• Anthracycline dose intensification in acute myeloid leukemia.

  2009influential reference
• Different dosage schedules for reducing cardiotoxicity in cancer patients receiving anthracycline chemotherapy.

  2009cited by this paper
• Longitudinal evaluation of early and late anthracycline cardiotoxicity in children with AML

  2008cited by this paper
• Longitudinal evaluation of early and late anthracycline cardiotoxicity in children with AML

  2007cited by this paper
• Anthracycline associated cardiotoxicity in survivors of childhood cancer

  2007cited by this paper
• Different dosage schedules for reducing cardiotoxicity in cancer patients receiving anthracycline chemotherapy.

  2006cited by this paper
• Less toxicity by optimizing chemotherapy, but not by addition of granulocyte colony-stimulating factor in children and adolescents with acute myeloid leukemia: results of AML-BFM 98.

  2006influential reference
• Treatment strategies and long-term results in paediatric patients treated in four consecutive AML-BFM trials

  2005cited by this paper
• Pediatric acute myeloid leukemia: international progress and future directions

  2005cited by this paper
• Early deaths and treatment-related mortality in children undergoing therapy for acute myeloid leukemia: analysis of the multicenter clinical trials AML-BFM 93 and AML-BFM 98.

  2004cited by this paper
• Pilot study of idarubicin-based intensive-timing induction therapy for children with previously untreated acute myeloid leukemia: Children's Cancer Group Study 2941.

  2004cited by this paper
• The Statistical Analysis of Failure Time Data

  2003influential reference
• Population pharmacokinetics of liposomal daunorubicin in children.

  2003cited by this paper
• The Statistical Analysis of Failure Time Data: Kalbfleisch/The Statistical

  2002cited by this paper
• [Liposomal daunorubicine combined with cytarabine in the treatment of relapsed/refractory acute myeloid leukemia in children].

  2002cited by this paper
• High‐dose liposomal daunorubicin and high‐dose cytarabine combination in patients with refractory or relapsed acute myelogenous leukemia

  2001cited by this paper
• Idarubicin improves blast cell clearance during induction therapy in children with AML: results of study AML-BFM 93

  2001cited by this paper
• Definition of a standard‐risk group in children with AML

  1999cited by this paper
• CARDIOPROTECTION

  1999cited by this paper
• A systematic collaborative overview of randomized trials comparing idarubicin with daunorubicin (or other anthracyclines) as induction therapy for acute myeloid leukaemia

  1998cited by this paper
• A systematic collaborative overview of randomized trials comparing idarubicin with daunorubicin (or other anthracyclines) as induction therapy for acute myeloid leukaemia

  1998cited by this paper
• Development of the model of rat isolated perfused heart for the evaluation of anthracycline cardiotoxicity and its circumvention

  1996cited by this paper
• Randomized phase III trial of liposomal daunorubicin versus doxorubicin, bleomycin, and vincristine in AIDS-related Kaposi's sarcoma.

  1996cited by this paper
• Daunoxome® Treatment of Solid Tumors: Preclinical and Clinical Investigations

  1994cited by this paper
• Treatment of newly diagnosed children and adolescents with acute myeloid leukemia: a Childrens Cancer Group study.

  1994cited by this paper
• Selective in vivo localization of daunorubicin small unilamellar vesicles in solid tumors.

  1992cited by this paper
• Report of the National Cancer Institute-sponsored workshop on definitions of diagnosis and response in acute myeloid leukemia.

  1990cited by this paper
• Tables of the number of patients required in clinical trials using the logrank test.

  1982cited by this paper
• Use of anionic liposomes for the reduction of chronic doxorubicin-induced cardiotoxicity.

  1981influential reference

• The Impact of Estimated Glomerular Filtration Rate at Diagnosis on Clinical Outcome in Children, Adolescents, and Young Adults with Acute Myeloid Leukemia

  2026cites this paper
• Improved outcomes and treatment guidance in pediatric therapy-related AML: AML-BFM study group recommendations

  2025cites this paper
• Emerging Strategies for the Prevention of Chemotherapy-Induced Cardiotoxicity in Paediatric Cancer Patients: Advances and Future Perspectives

  2025cites this paper
• Clinical Efficacy and Safety of a Modified Conditioning Regimen Reducing the Dosage of Busulfan and Adding Thiotepa in Allogeneic Hematopoietic Stem Cell Transplantation for Pediatric Acute Myeloid Leukemia.

  2025cites this paper
• Evaluating the Implementation Success of an Intensity‐Adapted Guideline for Pediatric Acute Myeloid Leukemia in Malawi: An Observational‐Implementation Study Protocol

  2025cites this paper
• Treatment outcomes and prognostic factors in children diagnosed with acute myeloid leukaemia in Uganda

  2025cites this paper
• Prognostic Value of Molecular Genetic Measurable Residual Disease (MRD) Monitoring in Pediatric Acute Myeloid Leukemia Expressing KMT2A::MLLT10

  2025cites this paper
• The role of epigenetic therapy in the treatment of childhood acute myeloid leukemia

  2025cites this paper
• The hallmarks of hematopoietic stem cell transplantation for pediatric acute myeloid leukemia

  2025cites this paper
• Paediatric acute myeloid leukaemia epidemiology, treatment approaches, and outcomes in africa: A review of the literature

  2025cites this paper
• Comparison of Consolidation Strategies for Pediatric Patients With Acute Myeloid Leukemia: Results of the Randomized GATLA 8-LMA-P'07 Trial.

  2025cites this paper
• Understanding the Mechanisms of Chemotherapy-Related Cardiotoxicity Employing hiPSC-Derived Cardiomyocyte Models for Drug Screening and the Identification of Genetic and Epigenetic Variants

  2025cites this paper
• Evaluating antifungal prophylaxis strategies in pediatric acute myeloid leukemia: a retrospective, single-center analysis of amphotericin B, itraconazole, and voriconazole

  2025cites this paper
• Long-term kidney complications in childhood leukemia survivors: a study from the Childhood and Adolescent Leukemia (LEA) project

  2025cites this paper
• Acute myeloid leukemias and myelodysplastic syndromes associated with previous cytotoxic therapy. Characteristic features, prognosis, and treatment approaches

  2025cites this paper
• Ocular involvement in pediatric patients with acute leukemia relapse: points of diagnosis and treatment

  2025cites this paper
• Prognostic Factors of Pediatric Acute Myeloid Leukemia Patients with t(8;21) (q22;q22): A Single-Center Retrospective Study

  2024cites this paper
• Mitoxantrone Versus Liposomal Daunorubicin in Induction of Pediatric AML With Risk Stratification Based on Flow Cytometry Measurement of Residual Disease

  2024cites this paper
• Prognostic value of myeloid-derived suppressor-like cells in acute myeloid leukemia: insights from immunophenotyping and clinical correlations

  2024cites this paper
• Structural Variance of Doxorubicin and Anthracycline Analogues as Topoisomerase Alpha and Beta (Top2a and Top2b) Inhibitors. Potential Design of Analogue Candidates of Less Side Effects on Cardiomyocytes.

  2024cites this paper
• Pediatric Cardio-Oncology: Screening, Risk Stratification, and Prevention of Cardiotoxicity Associated with Anthracyclines

  2024cites this paper
• Intensive chemotherapy with dual induction and ALL-like consolidation for childhood acute myeloid leukemia: a respective report from multiple centers in China

  2024cites this paper
• Optimized cytogenetic risk-group stratification of KMT2A-rearranged pediatric acute myeloid leukemia

  2024cites this paper
• Treatment outcome and prognostic factors in relapsed pediatric acute myeloid leukemia

  2023cites this paper
• The outcome in pediatric acute myeloblastic leukemia; results of the first-line treatment and contribution of hematopoietic stem cell transplantation to survival of relapsed patients

  2023cites this paper
• Gemtuzumab ozogamicin for relapsed or primary refractory acute myeloid leukemia in children—the Polish Pediatric Leukemia and Lymphoma Study Group experience

  2023cites this paper
• Rationale and design of the Children's Oncology Group study AAML1831 integrated cardiac substudies in pediatric acute myeloid leukemia therapy

  2023cites this paper
• Therapeutic targeting in pediatric acute myeloid leukemia with aberrant HOX/MEIS1 expression

  2023cites this paper
• Risk-Stratified Therapy for Pediatric Acute Myeloid Leukemia

  2023cites this paper
• BCR-ABL1 co-occurring with CBFA2T3-GLIS2 and RAM immunophenotype in a non-Down syndrome infant with acute megakaryoblastic leukemia

  2023cites this paper
• Relapsed childhood acute myeloid leukemia: prognostic factors and outcomes: experience from a single oncology center

  2023cites this paper
• Understanding WT1 Alterations and Expression Profiles in Hematological Malignancies

  2023cites this paper
• Genomic breakpoint-specific monitoring of measurable residual disease in pediatric non-standard-risk acute myeloid leukemia

  2023cites this paper
• Miliary leukemia cutis as extramedullary relapse of KMT2A rearranged pediatric AML

  2023cites this paper
• Measurable Residual Disease and Fusion Partner Independently Predict Survival and Relapse Risk in Childhood KMT2A-Rearranged Acute Myeloid Leukemia: A Study by the International Berlin-Frankfurt-Münster Study Group

  2023cites this paper
• Clinical Implications of the FLT3-ITD Allelic Ratio in Acute Myeloid Leukemia in the Context of an Allogeneic Stem Cell Transplantation

  2023cites this paper
• Clofarabine with topotecan, vinorelbine, and thiotepa reinduction regimen for children and young adults with relapsed AML

  2022cites this paper
• A clinical report on high‑dose cytarabine therapy for children with acute myeloid leukemia

  2022cites this paper
• BRD4 PROTAC degrader MZ1 exerts anticancer effects in acute myeloid leukemia by targeting c-Myc and ANP32B genes

  2022cites this paper
• 异基因造血干细胞移植治疗儿童急性髓系白血病（非急性早幼粒细胞白血病）中国专家共识（2022年版）

  2022cites this paper
• Acute myeloid leukemia secondary to acute B lymphoblastic leukemia treated with maintenance therapy in a child: A case report

  2022cites this paper
• Improved Outcome in Pediatric Acute Myeloid Leukemia: Progress With Hematopoietic Cell Transplantation

  2022cites this paper
• A phase III clinical trial evaluating efficacy and safety of minimal residual disease-based risk stratification for children with acute myeloid leukemia, incorporating a randomized study of gemtuzumab ozogamicin in combination with post-induction chemotherapy for non-low-risk patients (JPLSG-AML-20)

  2022cites this paper
• The outcomes of children with acute myeloid leukemia treated in accordance with the AML–MM-2006 protocol

  2022cites this paper
• Hypodiploidy has unfavorable impact on survival in pediatric acute myeloid leukemia: an I-BFM Study Group collaboration

  2022cites this paper
• Pediatric Acute Myeloid Leukemia—Past, Present, and Future

  2022cites this paper
• Cytarabine dose reduction in patients with low‐risk acute myeloid leukemia: A report from the Children's Oncology Group

  2021cites this paper
• Abdominal Complications During Treatment for Pediatric Acute Myeloid Leukemia

  2021cites this paper
• Role of Minimal Residual Disease Testing in Acute Myeloid Leukemia.

  2021cites this paper
• Efficacy and safety of induction chemotherapy with daunorubicin or idarubicin in the treatment of an adult with acute lymphoblastic leukemia

  2021cites this paper
• Design, synthesis and application of fluorogenic probe for detecting l-asparaginase in serum samples

  2021cites this paper
• Haploidentical Hematopoietic Stem Cell Transplantation with Post-Transplantation Cyclophosphamide in Children with High-Risk Leukemia Using a Reduced-Intensity Conditioning Regimen and Peripheral Blood as the Stem Cell Source.

  2021cites this paper
• Treatment of acute myeloid leukemia in children: A practical perspective

  2021cites this paper
• Akute myeloische Leukämie

  2021cites this paper
• Pediatric Acute Promyelocytic Leukemia: Epidemiology, Molecular Features, and Importance of GST-Theta 1 in Chemotherapy Response and Outcome

  2021cites this paper
• Outcome of pediatric acute myeloid leukemia (AML) in low- and middle-income countries: a systematic review of the literature

  2021cites this paper
• Treatment outcomes of pediatric acute myeloid leukemia: a retrospective analysis from 1996 to 2019 in Taiwan

  2021cites this paper
• Risk factors and prognostic analysis of acute myeloid leukemia in children

  2021cites this paper
• Results of a phase 2, multicenter, single‐arm, open‐label study of lenalidomide in pediatric patients with relapsed or refractory acute myeloid leukemia

  2021cites this paper
• Minimizing cardiac toxicity in children with acute myeloid leukemia.

  2021cites this paper
• Recent Advances in the Management of Pediatric Acute Myeloid Leukemia—Report of the Hungarian Pediatric Oncology-Hematology Group

  2021cites this paper
• Measurable residual disease monitoring of SPAG6, ST18, PRAME, and XAGE1A expression in peripheral blood may detect imminent relapse in childhood acute myeloid leukemia.

  2021cites this paper
• Advances in the First Line Treatment of Pediatric Acute Myeloid Leukemia in the Polish Pediatric Leukemia and Lymphoma Study Group from 1983 to 2019

  2021cites this paper
• USE OF ARTIFICIAL CELLS AS DRUG CARRIERS.

  2021cites this paper
• Clinical and biological aspects of myeloid leukemia in Down syndrome

  2021cites this paper
• Bortezomib with standard chemotherapy for children with acute myeloid leukemia does not improve treatment outcomes: a report from the Children’s Oncology Group

  2020cites this paper
• Epidemiological evaluation and survival of children with acute myeloid leukemia

  2020cites this paper
• Impact of allogeneic hematopoietic stem cell transplantation on pediatric acute myeloid leukemia of FAB subtypes M4 and M5

  2020cites this paper
• The influence of charge and lipophilicity of daunorubicin and idarubicin on their penetration of model biological membranes - Langmuir monolayer and electrochemical studies.

  2020cites this paper
• Measurable residual disease assessment by qPCR in peripheral blood is an informative tool for disease surveillance in childhood acute myeloid leukaemia

  2020cites this paper
• Late Effects after Treatment of Acute Myeloid Leukemia in Childhood and Adolescence

  2020cites this paper
• Second Relapse of Pediatric Patients with Acute Myeloid Leukemia: A Report on Current Treatment Strategies and Outcome of the AML-BFM Study Group

  2020cites this paper
• Attempts to optimize postinduction treatment in childhood acute myeloid leukemia without core‐binding factors: A report from the Japanese Pediatric Leukemia/Lymphoma Study Group (JPLSG)

  2020cites this paper
• Pharmacological prophylaxis of infection in pediatric acute myeloid leukemia patients

  2020cites this paper
• Paediatric Strategy Forum for medicinal product development for acute myeloid leukaemia in children and adolescents

  2020cites this paper
• Immune Response in a Pediatric Cancer Patient after a One-Week Skiing Intervention

  2019cites this paper
• Allogeneic hematopoietic stem cell transplantation for children and adolescents with high-risk cytogenetic AML: distinctly poor outcomes of FUS-ERG-positive cases

  2019cites this paper
• Response‐guided chemotherapy for pediatric acute myeloid leukemia without hematopoietic stem cell transplantation in first complete remission: Results from protocol DB AML‐01

  2019cites this paper
• Clinical and biological features of acute myeloid leukemia with MLL gene rearrangements in children and results of therapy according to protocols AML-MM-2000/2006 in the Republic of Belarus

  2019cites this paper
• Use of granulocyte colony‐stimulating factor and risk of relapse in pediatric patients treated for acute myeloid leukemia according to NOPHO‐AML 2004 and DB AML‐01

  2019cites this paper
• Utility of the number needed to treat in paediatric haematological cancer randomised controlled treatment trials: a systematic review

  2019cites this paper
• Differences in ex-vivo Chemosensitivity to Anthracyclines in First Line Acute Myeloid Leukemia

  2019cites this paper
• Measurable residual disease monitoring using Wilms tumor gene 1 expression in childhood acute myeloid leukemia based on child‐specific reference values

  2019cites this paper
• Equipotent doses of daunorubicin and idarubicin for AML: a meta-analysis of clinical trials versus in vitro estimation

  2019cites this paper
• Clofarabine Can Replace Anthracyclines and Etoposide in Remission Induction Therapy for Childhood Acute Myeloid Leukemia: The AML08 Multicenter, Randomized Phase III Trial.

  2019cites this paper
• Mutated WT1, FLT3-ITD, and NUP98-NSD1 Fusion in Various Combinations Define a Poor Prognostic Group in Pediatric Acute Myeloid Leukemia

  2019cites this paper
• Long noncoding RNA ZFAS1 enhances adriamycin resistance in pediatric acute myeloid leukemia through the miR-195/Myb axis

  2019cites this paper
• Flow-Cytometric Monitoring of Minimal Residual Disease in Pediatric Patients With Acute Myeloid Leukemia: Recent Advances and Future Strategies

  2019cites this paper
• Pharmacotherapy in Children and Adolescents: Oncology.

  2019cites this paper
• Pediatric acute myeloid leukemia: updates on biology, risk stratification, and therapy.

  2019cites this paper
• Nanomedicine review: clinical developments in liposomal applications

  2019cites this paper
• A concise review on cancer treatment methods and delivery systems

  2019cites this paper
• Metabolic profile of leukemia cells influences treatment efficacy of L-asparaginase

  2019cites this paper
• Treatments for children and adolescents with AML

  2019cites this paper
• Treatment of Childhood Acute Myeloid Leukemia in Bulgaria

  2018cites this paper
• Prevalence and characteristics of metabolic syndrome in adults from the French childhood leukemia survivors’ cohort: a comparison with controls from the French population

  2018cites this paper
• Successes and challenges in the treatment of pediatric acute myeloid leukemia: a retrospective analysis of the AML-BFM trials from 1987 to 2012

  2018cites this paper
• Epigenetic heterogeneity affects the risk of relapse in children with t(8;21)RUNX1-RUNX1T1-rearranged AML

  2018cites this paper
• Clinical challenges in de novo pediatric acute myeloid leukemia

  2018cites this paper
• Leukämien und Lymphome

  2018cites this paper